Microalbuminuria: Is it a valid predictor of cardiovascular risk?
Rodrigo Tagle, MD
Department of Nephrology and Hypertension, The Cleveland Clinic
Monica Acevedo, MD
Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic
Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension and Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, The Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Address: Donald Vidt, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: firstname.lastname@example.org
ABSTRACTMicroalbuminuria strongly predicts cardiovascular morbidity and mortality, clinical nephropathy, and progression of renal disease in high-risk populations. We recommend screening patients with type 2 diabetes, older patients with type 1 diabetes, and older patients with stage 2 hypertension or higher (ie, > or = 160/100 mm Hg).